Glaucoma Research Foundation

Rochester University researcher awarded 2017 Shaffer PrizeFor his research efforts to better understand the molecular pathways that are responsible for axonal degeneration in glaucoma, Richard Libby, PhD, was awarded the 2017 Shaffer Prize for Research during Thursday night’s Glaucoma 360 annual Gala.
Glaucoma 360 expands its ‘horizons’ with new program, sessionsOver the years, Glaucoma 360 has brought the concept of innovation in glaucoma to the forefront. This year’s meeting will surpass the Glaucoma Research Foundation’s (GRF) own “Horizons” by adding a few more “degrees” to its 360-degree concept.
Dr. de Juan receives Catalyst Award; opera singer Márquez gets Visionary AwardA renowned ophthalmologist and an accomplished opera singer were the highlight of Thursday night’s Glaucoma 360 annual Gala, when the two were presented with the Glaucoma Research Foundation’s (GRF) highest honors—The Catalyst Award and Visionary Award.
Glaucoma 360 approaches disease from every angleResearch. Industry. Philanthropy. These three facets—each with a unique purpose—will come together for the 2017 installment of the annual Glaucoma Research Foundation (GRF) Glaucoma 360 meeting. The three-day event will occur Feb. 2 to 4, 2016.
Check out a recap from the 2016 Glaucoma 360 gala!
Check out a recap from the 2016 Glaucoma 360 gala!From the silent auction, art sales, and an opera performance, the 2016 Glaucoma 360 gala was one not to be soon forgotten.
Three companies on the “Horizon” with glaucoma drugsThe pace of new glaucoma drug development continues, fueled by continuing research into novel mechanisms of action. Three companies, Aerie Pharmaceuticals, Bausch + Lomb, and Inotek Pharmaceuticals, shared their latest results.
B + L dedicated to eye care with strong portfolio, new programsBausch + Lomb (B + L) outlines the company's commitment to eye care with a strong portfolio, new programs, patient access, and better pricing.
FDA making changes in approval processes for industry, patientsThe laws governing ophthalmic drug and device approvals have changed little in recent years. But the FDA is making significant and far-reaching changes in its approvals process.
Allergan building presence in glaucoma with implant and MIGS deviceAllergan is moving forward with plans to introduce innovative drug delivery device and surgical device for glaucoma
Device makers swing for fence with new technologiesDevice manufacturers presenting new implants and technologies to treat glaucoma. As the industry moves from 1.0 devices to 2.0 devices, this will be a transformative time in the way physicians treat patients.